"RIV/00216224:14110/12:00061849!RIV13-MZ0-14110___" . . "Mich\u00E1lek, Jaroslav" . "Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy" . . . "1582-1838" . "P(2B06058), P(NT11137)" . . . "11"^^ . "Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy"@en . "Vop\u011Bnkov\u00E1, Kate\u0159ina" . "11" . "RIV/00216224:14110/12:00061849" . "Journal of Cellular and Molecular Medicine" . . . "Bure\u0161ov\u00E1, Ivana" . "Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy" . "14110" . . . . . . "10.1111/j.1582-4934.2012.01614.x" . "128174" . "Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy"@en . "Dendritic cell (DC) immunotherapy is capable of generating tumour-specific immune responses. Different maturation strategies were previously tested to obtain DC capable of anti-cancer responses in vitro, usually with limited clinical benefit. Mutual comparison of currently used maturation strategies and subsequent complex evaluation of DC functions and their stimulatory capacity on T cells was performed in this study to optimize the DC vaccination strategy for further clinical application. DC were generated from monocytes using granulocyte\u2013macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4, pulsed with whole tumour cell lysate and then matured with one of five selected maturation strategies or cultured without additional maturation stimulus. DC were characterized with regard to their surface marker expression, cytokine profiles, migratory capacity, allogeneic and autologous T cell stimulatory capacity as well as their specific cytotoxicity against tumour antigens." . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . "000310555200026" . . "4"^^ . . "Dendritic cell (DC) immunotherapy is capable of generating tumour-specific immune responses. Different maturation strategies were previously tested to obtain DC capable of anti-cancer responses in vitro, usually with limited clinical benefit. Mutual comparison of currently used maturation strategies and subsequent complex evaluation of DC functions and their stimulatory capacity on T cells was performed in this study to optimize the DC vaccination strategy for further clinical application. DC were generated from monocytes using granulocyte\u2013macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4, pulsed with whole tumour cell lysate and then matured with one of five selected maturation strategies or cultured without additional maturation stimulus. DC were characterized with regard to their surface marker expression, cytokine profiles, migratory capacity, allogeneic and autologous T cell stimulatory capacity as well as their specific cytotoxicity against tumour antigens."@en . "[15A211C952C0]" . "4"^^ . "16" . . . . . . . . "Mollov\u00E1, Kl\u00E1ra" . . "cancer immunotherapy; cytotoxicity; dendritic cell; interleukin-12; maturation; migration"@en . .